Shipping to United States We Offer Worldwide Shipping
Login Wishlist

1-Cinnamoylpyrrolidine

$480

  • Brand : BIOFRON

  • Catalogue Number : AV-B02998

  • Specification : 95%

  • CAS number : 52438-21-8

  • Formula : C13H15NO

  • Molecular Weight : 201.26

  • PUBCHEM ID : 765514

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B02998

Analysis Method

HPLC,NMR,MS

Specification

95%

Storage

-20℃

Molecular Weight

201.26

Appearance

Powder

Botanical Source

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

C1CCN(C1)C(=O)C=CC2=CC=CC=C2

Synonyms

(2E)-3-Phenyl-1-(1-pyrrolidinyl)-2-propen-1-one/Pyrrolidine, 1-cinnamoyl-/(2E)-3-phenyl-1-(pyrrolidin-1-yl)prop-2-en-1-one/2-Propen-1-one, 3-phenyl-1-(1-pyrrolidinyl)-, (2E)-

IUPAC Name

(E)-3-phenyl-1-pyrrolidin-1-ylprop-2-en-1-one

Applications

1-Cinnamoylpyrrolidine (Compound 3), a crude extract prepared from Piper caninum, is a DNA strand scission agent, induces the relaxation of supercoiled pBR322 plasmid DNA[1].1-Cinnamoylpyrrolidine (Compound 4) inhibits platelet aggregation induced by PAF with an IC50 of 37.3 μM[2].

Density

1.1±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

184.4±10.8 °C

Boiling Point

386.0±12.0 °C at 760 mmHg

Melting Point

123℃

InChl

InChl Key

JSIGICUAXLIURX-CMDGGOBGSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:52438-21-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

25741630

Abstract

In most vertebrates, the liver produces bile that is necessary to emulsify absorbed fats and enable the digestion of lipids in the small intestine as well as to excrete bilirubin and other metabolic products. In the liver, the experimental obstruction of the extrahepatic biliary system initiates a complex cascade of pathological events that leads to cholestasis and inflammation resulting in a strong fibrotic reaction originating from the periportal fields. Therefore, surgical ligation of the common bile duct has become the most commonly used model to induce obstructive cholestatic injury in rodents and to study the molecular and cellular events that underlie these pathophysiological mechanisms induced by inappropriate bile flow. In recent years, different surgical techniques have been described that either allow reconnection or reanastomosis after bile duct ligation (BDL), e.g., partial BDL, or other microsurgical methods for specific research questions. However, the most frequently used model is the complete obstruction of the common bile duct that induces a strong fibrotic response after 21 to 28 days. The mortality rate can be high due to infectious complications or technical inaccuracies. Here we provide a detailed surgical procedure for the BDL model in mice that induce a highly reproducible fibrotic response in accordance to the 3R rule for animal welfare postulated by Russel and Burch in 1959.

KEYWORDS

Medicine, Issue 96, bile duct ligation, cholestasis, bile obstruction, hepatic fibrosis, inflammation, extracellular matrix, jaundice, mouse

Title

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Author

Carmen G. Tag, 1 Sibille Sauer-Lehnen, 1 Sabine Weiskirchen, 1 Erawan Borkham-Kamphorst, 1 Rene H. Tolba, 2 Frank Tacke, 3 and Ralf Weiskirchen 1

Publish date

2015;

PMID

31968557

Abstract

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent an unlimited source of human CMs that could be a standard tool in drug research. However, there is concern whether hiPSC-CMs express all cardiac ion channels at physiological level and whether they might express non-cardiac ion channels. In a control hiPSC line, we found large, “noisy” outward K+ currents, when we measured outward potassium currents in isolated hiPSC-CMs. Currents were sensitive to iberiotoxin, the selective blocker of big conductance Ca2+-activated K+ current (IBK,Ca). Seven of 16 individual differentiation batches showed a strong initial repolarization in the action potentials (AP) recorded from engineered heart tissue (EHT) followed by very early afterdepolarizations, sometimes even with consecutive oscillations. Iberiotoxin stopped oscillations and normalized AP shape, but had no effect in other EHTs without oscillations or in human left ventricular tissue (LV). Expression levels of the alpha-subunit (KCa1.1) of the BKCa correlated with the presence of oscillations in hiPSC-CMs and was not detectable in LV. Taken together, individual batches of hiPSC-CMs can express sarcolemmal ion channels that are otherwise not found in the human heart, resulting in oscillating afterdepolarizations in the AP. HiPSC-CMs should be screened for expression of non-cardiac ion channels before being applied to drug research.

KEYWORDS

human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), iPS cells, stem cells, big conductance calcium activated potassium channel (BK), Maxi-K, slo1, KCa1.1, iberiotoxin, long QT syndrome

Title

Case Report on: Very Early Afterdepolarizations in HiPSC-Cardiomyocytes?An Artifact by Big Conductance Calcium Activated Potassium Current (Ibk,Ca)

Author

Andras Horvath,1,2,3,†‡ Torsten Christ,1,2,*† Jussi T. Koivumaki,4 Maksymilian Prondzynski,1,2,§ Antonia T. L. Zech,1,2 Michael Spohn,5 Umber Saleem,1,2 Ingra Mannhardt,1,2 Barbel Ulmer,1,2 Evaldas Girdauskas,2,6 Christian Meyer,3,7 Arne Hansen,1,2 Thomas Eschenhagen,1,2 and Marc D. Lemoine1,2,7,*

Publish date

2020 Jan;

PMID

30214311

Abstract

Purpose
To examine the association between selective serotonin reuptake inhibitor (SSRI) use and mortality, postoperative complications, and quality of in-hospital care in hip fracture patients.

Patients and methods
The study was a nationwide cohort study based on individual-level linked, prospectively collected data from Danish population-based national registries covering all hospitals in Denmark. The health care system in Denmark is tax-funded, and all citizens have equal access to health care services. We included patients with first-time hospitalization due to hip fracture undergoing surgery from 2006-2016. We estimated the risk of 30-day mortality, any unplanned readmission, any reoperation, specific postoperative complications including cardiovascular events and major bleeding, and quality of in-hospital care using Cox and Poisson regression analyses comparing current and former SSRI users with non-users.

Results
In 68,487 hip fracture patients, 13,272 (19%) were current SSRI users, 2,777 (4%) were former SSRI users, and 52,438 (77%) were SSRI non-users. The 30-day mortality risk was 13% in current SSRI users (HR 1.16, 1.10-1.21) and 12% in former (HR 1.15, 1.04-1.27) compared with 10% in non-users. The HR for any unplanned readmission was 1.11 (1.02-1.20) in current and 1.13 (1.01-1.27) in former SSRI users and for any reoperation 1.21 (1.11-1.31) in current and 1.04 (0.84-1.28) in former SSRI users compared with non-users. The risk of venous thromboembolism, myocardial infarction, stroke, and bleeding were similar irrespective of SSRI use. No association between current and former SSRI use and quality of in-hospital care was found.

Conclusion
In patients undergoing hip fracture surgery, 30-day mortality and overall readmission risk were elevated in both current and former SSRI users compared with non-users. Those currently using SSRI had a 26% increased reoperation risk compared with non-users. However, SSRI use was not associated with increased risk of other postoperative complications and lower quality of in-hospital care. A limitation of this study was the inability to control for potential confounding of social deprivation.

KEYWORDS

cohort studies, hip fracture, mortality, postoperative complications, quality of care, selective serotonin reuptake inhibitors

Title

Selective serotonin reuptake inhibitor use and mortality, postoperative complications, and quality of care in hip fracture patients: a Danish nationwide cohort study

Author

Stine Bakkensen Bruun,1 Irene Petersen,1,2 Nickolaj Risbo Kristensen,1 Deirdre Cronin-Fenton,1 and Alma Becic Pedersen1

Publish date

2018;